Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers/Epidemiology/Outcomes

Gastrointestinal (Colorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.

Ana Barat

e15584

A nomogram to predict overall survival in colorectal cancer patients based on new inflammation-nutrition score and TNM stage.

Shiki Fujino

e15625

A novel prognostic prediction model for recurrence in patients with stage II colon cancer after curative resection.

Kazuhiro Saso

e15615

A prospective cohort study in colorectal cancer assessing the relationship between post-surgery detection of methylated BCAT1 or IKZF1 ctDNA and risk for residual disease and survival.

David Murray

3596

Adjuvant chemotherapy and survival outcomes in diabetic patients with colon cancer: A population-based analysis.

Shiru Lucy Liu

3589

Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorectal cancer patients and healthy controls.

Deniz Can Guven

e15617

Analysis of circulating tumor DNA to monitor disease status in colorectal cancer after surgery.

Liren Li

e15583

Association between density of tumor infiltrating lymphocytes and disease-free survival (DFS) in patients with resected stage I-III colorectal cancer in the FACS randomized trial.

Sian Alexandra Pugh

3573

Association between microsatellite instability and BRAF, TP53, PTEN, and KRAS mutations in colorectal cancer.

Maher Albitar

e15604

Association of a novel set of 7 homopolymer indels for detection of MSI with tumor mutation burden and total indel load in endometrial and colorectal cancers.

Hui Zhao

e15654

Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.

Edouard Auclin

3568

Bax/Bcl-2 and caspase 3 pathway-mediated apoptosis induced by gentiopicroside in human colorectal cancer cells.

Yun Yang

e15665

Body mass index and long-term outcomes in patients with colorectal cancer.

Dorin Colibaseanu

e15631

Cancer stem cells in colorectal tumors of various extents.

Elena Yurievna Zlatnik

e15659

Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).

Rahul K Das

3570

Chemotherapy to reverse diminished immune responses (IRs) associated with a raised neutrophil lymphocyte ratio (NLR) in patients with advanced colorectal cancer (aCRC).

Samantha J. Turnbull

e15635

Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment.

Thomas Tuxen Poulsen

e15577

Clinical and morphological characterization for detection of hypermutation in colorectal cancer.

Yoshifumi Shimada

e15647

Clinical factors to predict the absence of benefit of surgery in patients operated for colorectal liver metastases.

Ali Bohlok

e15613

Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of 5-FU based adjuvant chemotherapy in patients with stage II-III colorectal cancer: 10-year follow up results.

Hiromichi Sonoda

e15605

Clinical relevance of primary tumor site and respective molecular characteristics in patients with early-stage colorectal cancer.

Elena Fountzilas

e15606

Clinicopathological and genetic features of patients with colorectal cancer containing mucinous component.

Liu Yang

e15661

Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?

Marta Schirripa

3590

Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia.

Todd Yezefski

LBA3579

Comprehensive genomic profiling of colorectal cancers with and without microsatellite instability (MSI) and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST).

Kien Thiam Tan

e15620

Concordance in RAS mutation status between liquid and solid biopsies in subjects with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in first-line treatment in Spain: PERSEIDA study (NCT02792478).

Manuel Valladares-Ayerbes

e15602

Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).

Michael Lam

e15600

ctDNA sequencing for early detection of colorectal cancers: Comparative analysis of colon cancer and rectal cancer data.

Xiaoni Zhang

e15653

Detection of ctDNA biomarkers post resection and relationship to recurrent disease in colorectal cancer patients.

David Murray

e15616

Detection of microsatellite instability (MSI) in colorectal cancer samples with a novel set of highly sensitive markers by means of the Idylla MSI Test prototype.

Bram De Craene

e15639

Difference in immune infiltration in MSI and MSS BRAF mutant colorectal cancer.

Elena Bolzacchini

e15624

Differences in the characteristics of younger and older MSI-H colorectal cancer (CRC) as determined by universal reflex testing.

Aaron J Franke

3593

Distinct somatic alterations in right- versus left-sided colorectal cancers.

Robin Imperial

3592

Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT).

Patrick Hilden

3581

Effect of knockdown of eukaryotic initiation factor 4A2 (eIF4A2) on growth, metastasis, and oxaliplatin sensitivity in colorectal cancer.

Zhan-Hong Chen

e15658

Evaluation of the prognostic value of the lymph-node ratio in patients with colon cancer in the oxaliplatin era.

Darragh Connell

e15666

Expression of podocalyxin-like protein and epidermal growth factor receptor in metastatic colorectal cancer: Prognostic impact and relationship with response to cetuximab.

Anna H Larsson

e15587

Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.

Stephen B. Gruber

3575

Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology).

Kathryn Penney

3582

Genomic feature differences in APC-mutant and wild-type colorectal cancer patients.

Jing Hu

e15609

Genomic profiling of early-onset metastatic Chinese colorectal cancer (mCRC) patients: The development of a PFS prediction model for first line treatments.

Xicheng Wang

e15657

Identification of disease specific methylation markers and utilization in non-invasive colorectal cancer (CRC) diagnostics via deep cfDNA methylation sequencing.

Jinke Sui

e15610

Identification of potential oncogenic LncRNA RP11-474D1.3 in colorectal cancer.

Jialin Yang

e15611

Identification of very rare clinically actionable KRAS variants in colorectal cancer patients using a comprehensive large gene panel.

Shyamal Dilhan Weeraratne

e15632

Immune profile of BRAF mutated metastatic colorectal tumors with good prognosis.

Jeong Eun Kim

e15586

Impact of metformin use on pathologic response following chemoradiotherapy in rectal cancer.

Theodore Seth Thomas

e15642

Impact of microsatellite instability status and sidedness of the primary tumor on immunophenotype of colorectal cancer.

Chen Yang

e15664

Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.

Mohamed E. Salem

3572

Impact of tumor location and variables associated with overall survival in patients with colorectal cancer.

Cassia B Wang

e15651

Improvement of metastatic colorectal cancer patient survival: Single institution experience.

Elisabetta Fenocchio

e15633

International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.

Satoshi Fujii

3594

John Cunningham virus infection and the risk of colorectal cancer: A meta-analysis of case-control studies.

Lenka J Kimla

e15650

KIFC1 as a novel therapeutic target for p53 mutant colorectal cancer.

Karuna Mittal

e15585

Loss of TP53 as a prognostic biomarker of poor survival in stage III colorectal cancer patients.

Lincoln Nadauld

e15588

Lympho-platelets relationship as a prognostic factor for advanced colorectal cancer.

Eduardo Richardet

e15667

Meta-analysis reveals multiple drivers of colorectal cancer pathogenesis.

Kamal Khorfan

e15601

Metastatic disease representation: An analysis of 148 paired colorectal cancer lymph node metastatic tumour deposits.

Lennard YW Lee

e15595

Metastatic patterns and prognostic significance of signet ring cell carcinoma of the colon: Retrospective analysis of SEER database.

John Khoury

e15594

Metformin and stage IV colorectal cancer in elderly.

Rohit Bishnoi

e15636

Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).

Megan Jagosky

3577

Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer.

Yuji Takayama

e15630

MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study.

Siraj Mahamed Ali

3574

Neoangiogenesis factors determine incidence rates of colorectal cancer in men and women.

Elena Alekseevna Dzhenkova

e15623

Neutrophil/lymphocyte ratio as surrogate of cetuximab antibody-dependent cell-mediated cytotoxicity in first line metastatic colorectal cancer: A preliminary and exploratory analysis of the ERMES phase III trial.

Maria Alessandra Calegari

e15656

Night shift work duration and risk of colorectal cancer according to IRS1 and IRS2 expression.

Yan Shi

3571

Outcome of chemotherapy with or without targeted therapy in metastatic colorectal cancer with deficient mismatch repair phenotype: A cohort study in a single center.

Yue Yu

e15669

Paradoxical survival of Hispanics with colorectal cancer: SEER-based cohort.

Mahmoud Chaker

e15652

Patient and tumor-related factors for sphincter-preserving surgery in patients with rectal cancer.

Faisal Shahjehan

e15628

Performance of two immunoafinity-based methods for CTC detection and molecular characterization in advanced colorectal cancer.

Santiago Cabezas-Camarero

e15648

Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.

Francesca Battaglin

3576

Precision medicine in the real-world: The impact of the genetic testing evolution in metastatic colorectal cancer.

Adrianne Waldman Casebeer

e15612

Prevalence of KRAS and NRAS mutations in patients with metastatic colorectal cancer in Argentina: A multicenter prospective observational study.

Gabriela Marechal

e15608

Prevalence of MSI status in locally advanced rectal cancer and its correlation with response to neoadjuvant therapy and survival.

Nikhil Pande

e15668

Primary tumor sidedness in colorectal cancer at VA hospitals: A nation-wide study.

Ibrahim Azar

e15638

Profiling for microsatellite instability (MSI) and mismatch repair (MMR) among patients with colon cancer in real world settings.

Tracy Ann Proverbs-Singh

e15622

Prognostic evaluation of a new class of liquid biopsy biomarkers in patients with metastatic colorectal cancer: Using the tumor microenvironment as a source of protein biomarkers.

Stephanie Nina Kehlet

3588

Prognostic immune scoring of colorectal cancer liver metastasis with MHC class-I expression combined to T cell quantification.

David Henault

3586

Prognostic impact of BRAF V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis.

Sashidhar Manthravadi

3597

Prognostic significance of microsatellite instability (MSI) and mismatch repair status (MMR) in African American (AA) patients with colorectal cancer (CRC) and its impact on therapy with 5Fluorouracil.

Shahla Bari

e15634

Prognostic significance of number versus location of positive mesenteric nodes in node positive colon cancer.

Kozo Kataoka

3587

Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.

Nouredin Messaoudi

3584

Prognostic value of tumour infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study.

Ann Christina Eriksen

3580

Racial disparities in colorectal cancer survival: A population-based cohort.

Muneer J Al-Husseini

e15643

Racial disparities in the diagnosis, surgical management and survival of right sided and left sided colon cancers.

Sanjay R. Jain

e15660

Ratio of M2 tumor-associated macrophages as a better prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer.

Jianmin Xu

e15582

Real world survival outcomes in patients with high risk stage II colon cancer at a Beijing Cancer Hospital.

Aiwen WU

e15670

Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

Zev A. Wainberg

3578

RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs).

Iain BeeHuat Tan

e15597

SATB2 loss and the immune milieu of colorectal cancer (CRC).

Darran O'Connor

3569

Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial.

Jens T Siveke

e15599

Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).

Jeanne Tie

3516

Single nucleotide polymorphisms within Mucin-type O-glycan genes are associated with colorectal cancer survival.

Shun Lu

e15607

Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).

Volker Heinemann

3591

Study on the relationship between microsatellite status and clinicopathological characteristics of colorectal cancer patients after surgery.

Meili Chen

e15645

Survival benefit of obesity in stage IV colorectal cancer: Better tolerability of chemotherapy?

Catherine G Tran

e15629

The alternative NF-κB pathway in colorectal cancer: From genetic polymorphisms through mRNA to protein levels.

Anna G Antonacopoulou

e15619

The characteristics of ARID1A mutations in colorectal cancer.

Amir Mehrvarz Sarshekeh

3595

The clinical features and genomic landscape of elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in patients with colorectal cancer.

Ming Huang Chen

e15591

The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.

Roberto Moretto

e15593

The impact of skeletal muscle and adipose tissue on long-term survival in patients with resectable colorectal cancer.

Michael B. Sawyer

3585

The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.

Ryuma Tokunaga

e15578

The mutational landscape of circulating cell free DNA in patients with colorectal adenoma and carcinoma.

Ying Hu

e15662

Tumor purity as a prognostic factor in colon cancer.

Jianmin Xu

e15646

Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.

Mark Glaire

3515

Unplanned delays among patients receiving FOLFOX chemotherapy for colorectal cancer.

Lawrence Kogan

e15637

Validation of omics based MSI calling to improve upon traditional methods of MSI detection.

Andrew Nguyen

e15663

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).

Frank A. Sinicrope

3583